Additionally, CXCR4 antagonism (AMD3100) (Figure 1) reverts the suppressive activity of activated Tregs (CTLA4+/CXCR4+/PD-1+/ICOS+) in renal cancer (87) or reprograms Tregs in human mesothelioma (88). This evidence concerns the gene CXCR4 and renal carcinoma.